Global Plasma Protein Therapeutics Market Report and Forecast 2024-2032

Global Plasma Protein Therapeutics Market Outlook

The global plasma protein therapeutics market size was valued at USD 30.4 billion in 2023, driven by increasing demand for plasma protein therapies across the globe. The market size is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032 to achieve a value of USD 51.8 billion by 2032.

Plasma Protein Therapeutics: Introduction

Plasma-derived therapies play a crucial role in enhancing the quality of life for individuals by replacing missing or deficient proteins. These therapies are often a lifeline for patients who rely on them, necessitating regular infusions or injections throughout their lifetimes. The conditions treated by plasma protein therapies are typically categorized as rare diseases since they affect a relatively small percentage of the population, with many being genetic and chronic in nature.

Global Plasma Protein Therapeutics Market Analysis

The market is experiencing robust growth driven by the increase in demand for plasma protein therapies, particularly for conditions like hemophilia and Primary Immunodeficiency Disorders (PID), along with various other medical conditions. Novel drug therapies have gained high acceptance and accessibility, further fuelling the market expansion. Moreover, there is a significant increase in research and development efforts as well, particularly in the field of hemophilia therapy, contributing to the global plasma protein therapeutics market growth.

Additionally, the rising prevalence of autoimmune disorders has further amplified the demand for plasma protein therapeutics. Immunoglobulins are taking the lead in the product landscape, underscoring their importance in treating various medical conditions.

Global Plasma Protein Therapeutics Market Segmentations

Market Breakup by Product Type

• Immunoglobulin

• Albumin

• Plasma Derived Factor

• Others

Market Breakup by Applications

• Hemophilia

• Idiopathic Thrombocytopenic Purpura

• Primary Immunodeficiencies

• Other Applications

Market Breakup by End User

• Hospitals

• Home Care

• ASCs

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Plasma Protein Therapeutics Market Overview

The market is experiencing substantial growth driven by factors such as continuous product innovations in the field of plasma protein therapeutics adding options to existing treatment options and improving patient outcomes. The market is also driven by the increasing prevalence of autoimmune disorders and genetic disorders worldwide resulting in increased demand for these therapies, further propelling the plasma protein therapeutics market demand. The rising geriatric population that often requires such treatments has contributed to the market growth as well.

Government initiatives aimed at improving healthcare accessibility and affordability also play a pivotal role in fuelling the market's upward trajectory. Moreover, there is an escalating demand for albumin and an increased use of plasma proteins in pharmaceuticals, underlining their critical role in various medical treatments. Furthermore, the rising usage of immunoglobulin therapies has added to the market's overall growth, making the market a vibrant and evolving sector within the healthcare sector.

Global Plasma Protein Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• CSL Limited

• Baxter International

• Bio Products Laboratory Ltd

• Octapharma AG

• Kedrion, SpA 

• Becton, Dickinson and Company

• Takeda Pharmaceutical

• Grifols, S.A.

• ADMA Biologics Inc

• Bayer AG

Key Highlights of the Report